Your session is about to expire
← Back to Search
Long-Term Safety of Filgotinib for Rheumatoid Arthritis (FINCH 4 Trial)
FINCH 4 Trial Summary
This trial will study the long-term safety of the drug filgotinib in people who have completed other trials testing the drug's effectiveness in treating rheumatoid arthritis.
FINCH 4 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowFINCH 4 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 3 trial • 449 Patients • NCT02873936FINCH 4 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I'm sorry, I cannot provide a summary for this screening criterion as it is incomplete. Please provide more information.I completed a Gilead filgotinib study for RA and may benefit from continuing it.There may be additional requirements for participation in the study that are not listed here.You have a joint disease other than rheumatoid arthritis that could be risky or affect the study results, according to the doctor's judgment.This criterion does not apply to me.I am a woman who can have children and I have a negative pregnancy test before starting the study drug.I agree to use birth control as per the study's requirements.
- Group 1: Blinded Phase: Filgotinib 100 mg
- Group 2: Open Label Phase: Filgotinib 200 mg
- Group 3: Open Label Phase: Filgotinib 100 mg
- Group 4: Blinded Phase: Filgotinib 200 mg
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the potential Filgotinib side effects for consumers?
"Filgotinib's efficacy is supported by some data, and it has received multiple rounds of safety testing, so we've given it a 3."
Are people currently being signed up for this clinical trial?
"Currently, this clinical trial is not enrolling patients. However, it was updated as recently as October 20th, 2022. For those looking for other studies, there are 399 trials for rheumatoid arthritis and 9 Filgotinib trials that are currently recruiting patients."
Did prior research focus on Filgotinib's effects?
"The first study of filgotinib was completed in 2014 at Clinica de Especialidades Medicas. As of right now, there have been a total of 14 studies with 9 more currently underway. The locations for these active studies are primarily in San Antonio, Texas."
To the best of your knowledge, does a study like this exist?
"Gilead Sciences sponsored the first Filgotinib trial in 2014. Since then, this medication has undergone 9 clinical trials spanning 50 different countries and 202 cities."
Are there many medical facilities participating in this research project within the city limits?
"In total, 74 clinics are running this trial; a few examples include Arthritis & Osteoporosis Center of South Texas in San Antonio, Trinity Universal Research Associates, Inc in Plano, and Omega Research Consultants LLC in Orlando."
How many individuals are being monitored in this experiment?
"This study is not recruiting participants at the moment, as shown by its clinical trial post from February 28th, 2017 that was last edited on October 20th, 2022. However, there are 399 other trials for rheumatoid arthritis and 9 studies specifically for Filgotinib that are actively admitting patients."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger